

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (Previously Presented) A nucleic acid encoding a modified polypeptide with an improved *in vivo* half-life, said modified polypeptide comprising an Ig constant domain or Ig-like constant domain and a salvage receptor binding epitope within said Ig constant domain or Ig-like constant domain, wherein said epitope is absent from the unmodified polypeptide, wherein said salvage receptor binding epitope is taken from one loop of the CH<sub>2</sub> domain of an Fc region of an Ig molecule and wherein said polypeptide in modified form does not comprise an intact CH<sub>2</sub> domain or an intact Fc region.

2-20. (Cancelled)

21. (Previously presented) The nucleic acid of claim 1 wherein the Ig domain or Ig-like domain comprises a CH<sub>1</sub> domain.

22. (Currently Amended) The nucleic acid of claim 1 wherein the unmodified polypeptide is ~~an a~~ Fab, ~~an~~ (Fab)<sub>2</sub>, a (Fab')<sub>2</sub>, a diabody, a Fv fragment, a single chain Fv fragment, or a receptor.

23. (Currently Amended) The nucleic acid of claim 22 wherein the unmodified polypeptide is an anti-CD18 Fab or an anti-CD18 ~~(Fab)<sub>2</sub>~~ F(ab')<sub>2</sub>.

24. (Currently Amended) The nucleic acid of claim 23 wherein the ~~modified polypeptide~~ antiCD18 Fab or antiCD18 F(ab')<sub>2</sub> is human or humanized.

25. (Previously Presented) The nucleic acid of claim 1 wherein said salvage receptor binding epitope comprises amino acids from 1 through 11 of SEQ ID NO:3.

26-27. (Cancelled)

28. (Currently Amended) The nucleic acid of ~~any one~~ claim[[s]] 1 ~~or 26~~, wherein the unmodified polypeptide is selected from the group consisting of an antibody directed against CD11a or CD18 or both, a soluble form of ICAM-1, an antibody to ICAM-1, and fragments thereof ~~LFA-1 antagonist, a growth hormone and a nerve growth factor.~~

29. (Currently Amended) A vector comprising the nucleic acid of any one of claims 1, 21-25, and 28 ~~and 21-28~~.

30. (Currently Amended) A host cell comprising the nucleic acid of any one of claims 1, 21-25, 28, and 29 ~~and 21-28~~.

31. (Previously Presented) A method for producing a modified polypeptide comprising culturing the host cell according to claim 30 in a culture medium and recovering the modified polypeptide.

32. (New) The nucleic acid of claim 1, wherein the unmodified polypeptide is a growth hormone or a nerve growth factor.